Antimicrotubule benzimidazoles inhibit in vitro growth of Pneumocystis carinii

Antimicrob Agents Chemother. 1992 Apr;36(4):779-82. doi: 10.1128/AAC.36.4.779.

Abstract

Nine antimicrotubule benzimidazole derivatives tested in a Pneumocystis carinii culture system with human embryonic lung fibroblast monolayers inhibited organism proliferation. The concentrations of drugs inhibitory in culture ranged from 10 to 0.1 micrograms/ml, with thiabendazole being the least effective (10 micrograms/ml) and parbendazole being the most effective (0.1 microgram/ml). The parent compound, benzimidazole, was inactive at 10 micrograms/ml. Demonstration that this group of compounds has activity against P. carinii provides a new potential target that can be exploited, the microtubules. Also, the variability in the effectiveness of the compounds provides the basis for studies of structure-activity relationships, which were initiated in this study.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antiprotozoal Agents / pharmacology*
  • Benzimidazoles / pharmacology*
  • Microtubules / drug effects*
  • Pneumocystis / drug effects*
  • Pneumocystis / growth & development

Substances

  • Antiprotozoal Agents
  • Benzimidazoles